(Wiley-Blackwell) The Food and Drug Administration received reports of malignancies in children using tumor necrosis factor a (TNF) blockers, raising concerns of an associated risk and prompting an investigation. Researchers from the FDA set out to identify all reports of malignancy in children using infliximab, etanercept, and adalimumab and their report is published in the August issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology.
Read »Navigation
User login
Visit the BiotechMashup Blog
Best upcoming scoops - Chemistry
- Mayo Clinic study finds mild cognitive impairment is more common in men
- New and unique tool eases the process of finding article reviewers
- Antibiotics: Longer treatment times that benefit children may cost society
- Bipolar disorder does not increase risk of violent crime
- Morning sickness: Still no relief